Carboplatin-paclitaxel chemotherapy combination is the standard first-line treatment of advanced ovarian cancer and is the most commonly used treatment combination shown to be effective in advanced non-small-cell lung cancer (NSCLC). The most important dose-limiting side effect is hematologic toxicity. In this study, the severity of treatment-related myelotoxicity is compared in patients with advanced ovarian and lung cancers who received same schedule of carboplatinpaclitaxel. The study was prospectively performed from February 2009 to July 2011 and involved 103 patients with stages Ic-IV ovarian (n 5 51) and advanced NSCLC (n 5 52) who were administered a maximum of 6 cycles of carboplatin-paclitaxel as a first-line treatment. Full blood counts were measured before treatment, before each chemotherapy cycle during therapy, and at the first and sixth month after therapy. The median ages were 59 years (range, 35-77 years) for patients with NSCLC and 56 years (range, 38-75 years) for patients with ovarian cancer. The frequencies of anemia were 17% and 28.6% before the initiation of chemotherapy, 39.2% and 68.0% at the third cycle of treatment, and 44.2% and 45.2% at the sixth cycle of treatment in patients with NSCLC and ovarian cancer, respectively. Initial leukopenia rates were 3.4% and 0%; at the third cycle 46.0% and 41.2%; and at the sixth cycle 41.9% and 48.8% in patients with NSCLC and ovarian cancer, respectively. At the third cycle, 2.5% of the patients with NSCLC and 10.4% of the patients with ovarian cancer had thrombocytopenia, and at the sixth cycle, 23.3% of the patients with NSCLC and 25% of the patients with ovarian cancer had thrombocytopenia. Hemoglobin, leukocyte, and platelet values at the third cycle were significantly lower than those at admission in both cancer groups. Declines in hemoglobin levels in patients with NSCLC and in platelets in patients with ovarian cancer at the sixth cycle were statistically significant compared with the third cycle. In conclusion, the same schedule of chemotherapy may lead to different myelotoxicities in different types of cancer. These results should be taken into consideration in terms of supportive care and management of toxicity.
INTRODUCTION
Among all malignancies, non-small-cell lung cancer (NSCLC) is the leading cause of death for the global population, whereas ovarian cancer is the most fatal gynecologic malignancy. In both types of cancer, diagnosis is generally made in advanced stages, and treatment is based on the combinations of platinum derivatives.
Systemic therapy also improves the survival and quality of life of patients with advanced stage NSCLC. Carboplatin-based regimens are easy to administer in the outpatient setting and have favorable nonhematologic toxicity profiles compared with cisplatin-based regimens. Several studies have been conducted to compare carboplatin-based regimens with cisplatin-based combinations in the first-line treatment of advanced NSCLC. A 4-arm, randomized phase III study, the Eastern Cooperative Oncology Group (ECOG) 1594 trial, was conducted to compare the efficacies and toxicity profiles of cisplatin plus gemcitabine, cisplatin plus docetaxel, and carboplatin plus paclitaxel, with a reference regimen of cisplatin plus paclitaxel. 1 No significant differences in survival were observed among the 4 commonly used regimens; however, the carboplatin and paclitaxel regimen had a lower rate of toxic effects compared with the other regimens. The primary role of chemotherapy in patients with advanced NSCLC is palliative, but carboplatin-paclitaxel represents a viable alternative, with a similar response rate, a good safety profile, manageable toxicity, and superior ease of administration. As a result of their single-agent activities and synergistic effects, taxane-platinum combinations are often used as the first-line therapy for this disease.
A number of studies have compared the efficacy of cisplatin-paclitaxel with carboplatin-paclitaxel for the treatment of ovarian cancer proving ultimately that the carboplatin regimen is better tolerated. [2] [3] [4] [5] [6] Side effects, such as emesis, nephrotoxicity, ototoxicity, and neurotoxicity, were more favorable with carboplatin compared with cisplatin. As a result, carboplatin and paclitaxel have become the current standard of care for the primary treatment of ovarian cancer. [7] [8] [9] The most common clinical toxicities of the carboplatinpaclitaxel combination include alopecia, peripheral sensorial neuropathy, and mucositis; however, one of the main drawbacks of the regimen carboplatin-paclitaxel is its dose-limiting and cumulative myelosuppression characterized by granulocytopenia, thrombocytopenia, and anemia. Most of the patients with NSCLC are men and smokers in contrast to ovarian cancer. Women may experience greater degrees of anemia because of menstruation and may have differences in bone marrow function depending on hormonal status. It is unknown whether this combination causes similar myelotoxicity in the first-line treatments of different types of cancer. The objective of this study was to compare the degrees of myelotoxicity of the carboplatin-paclitaxel combination using the same doses and schedules in patients with advanced ovarian and lung cancer.
MATERIALS AND METHODS

Patient population
Between February 2009 and June 2011, 103 adult patients with histologically or cytologically confirmed epithelial ovarian (n 5 51) and advanced NSCLC (n 5 52) were consecutively included in this prospective study. The stagings were done according to TNM (tumor node and metastasis, classification of the International Union Against Cancer) and FIGO (International Federation of Gynecologic Oncology) staging system for NSCLC and ovarian cancer, respectively.
The inclusion criteria of patients were an ECOG performance status (PS) of 0-2, no radiotherapy, and adequate levels of bone marrow, hepatic, and renal function. To prevent the bias of cumulative toxicity, patients who received prior cycles of chemotherapy were excluded from the study. Patients with ECOG levels of 3 or 4, those with other concomitant diseases that might represent contraindications to treatment drugs, or those with previous or concomitant other malignancies were excluded. The local institutional scientific committee approved the study, and all the patients provided written informed consent before participating. The prospective study met the requirements of the Declaration of Helsinki.
Baseline evaluation
The pretreatment assessment included a medical history and physical examination (including an evaluation of ECOG PS), cardiac function testing (electrocardiography and echocardiography), and the measurement of laboratory parameters (complete blood count and serum biochemistry). Computed tomography or magnetic resonance imaging studies were performed at the baseline, after 3 and 6 cycles of chemotherapy. The response evaluation was in accordance with Response Evaluation Criteria in Solid Tumors version 1.0. 10 The treatment was prolonged to 6 cycles in responsive patients after 3 cycles of chemotherapy.
Carboplatin-paclitaxel treatment schedule
All patients received the following chemotherapy regimen: paclitaxel at a dose of 175 mg/m 2 and carboplatin that was dosed according to the Calvert formula for the desired area under the curve of 5 on day 1 of a 3-week cycle, for 6 courses. All patients received standard antiemetic agents and prophylaxis for paclitaxelassociated hypersensitivity reactions. The carboplatin dose was not modified unless the patients experienced complicated grade 3 or 4 neutropenia or thrombocytopenia requiring platelet transfusion. The treatment was delayed when patients were unable to recover from a hematologic toxicity. Granulocyte colony-stimulating support (G-CSF) was used to increase neutrophil counts when grade 4 toxicity occurred, and the carboplatin dose was reduced to area under the curve 4. Thrombocyte transfusion was performed because platelet level was lower than 10,000.
Assessment of toxicity
Toxic effects were evaluated before each new treatment cycle and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. 11 Complete biochemistry and blood counts were carried out before each cycle of chemotherapy, at the first month, and at the sixth month after therapy. In addition, complete blood counts were repeated between cycles in the case of fever, hemorrhagic manifestations, or severe mucositis. Patients were required to have an absolute neutrophil count of at least 1500/mm 3 and a platelet count of at least 100,000/mm 3 on the first day of course. Treatment was discontinued in patients with progression or severe toxicity despite sufficient dose reduction.
Statistical analysis
Data are reported as the mean, median, range, counts, and percentages when appropriate. The significance of differences during treatment compared with pretreatment values was evaluated by paired t tests, and the differences between groups of patients were assessed by independent-sample t tests for hemoglobin. The differences for leukocytes and platelets values, within and among different groups, were evaluated by the Wilcoxon matched-pairs signed-ranked test and the Mann-Whitney test, respectively. All P values were derived from 2-sided tests of statistical significance. P values ,0.05 were considered statistically significant. SPSS version 16.0 (SPSS, Inc., Chicago, IL) was used for the statistical analyses.
RESULTS
The median ages were 56 years (range, 38-75 years) for patients with ovarian cancer and 59 years (range, 35-77 years) for patients with NSCLC. Majority of the patients were ECOG PS 0-1. The most common histological subtype was the serous papillary type (72.5%) for patients with ovarian cancer and adenocarcinoma and squamous cell carcinoma for the patients with NSCLC. Most of the patients with ovarian cancer (72.5%) were determined to be stage IIIc according to the FIGO classification, and 84.8% of the patients with NSCLC were determined to be stage IV with respect to the revised TNM staging system. The other demographic and disease characteristics of patients in both groups are shown in Table 1 . 
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Adherence to treatment
Six cycles of treatment were completed by 82% of the patients with NSCLC and 90% of the patients with ovarian cancer. The treatment delay rates because of toxicity were determined to be 29% for the patients with ovarian cancer and 24% for the patients with NSCLC.
Toxicity
Effects on erythrocytes
The mean hemoglobin levels of patients with NSCLC were 13.01 6 1.61 g/dL (n 5 52) before the initiation of chemotherapy, 11.57 6 1.72 g/dL (n 5 51) at the third chemotherapy cycle, and 10.95 6 1.60 g/dL (n 5 43) at the sixth chemotherapy cycle ( Table 2) . Hemoglobin levels were 12.90 6 0.83 g/dL and 13.38 6 0.93 g/dL at the first and sixth month after therapy, respectively. Compared with the baseline values, a significant decrease was observed in hemoglobin levels at the third cycle (1.44 g/dL, P , 0.0001). Hemoglobin levels measured at the sixth cycle were significantly lower compared with those measured after the third cycle (0.5 g/dL, P , 0.0001) ( Table 2 ). Analysis of hemoglobin levels in patients with NSCLC revealed the rates of anemia to be 17.3% (all grades 1-2) before treatment, 39.2% (35.3%, grades 1-2 and 3.9%, grades 3-4) at the third cycle, and 44.2% (37.2%, grades 1-2 and 7.0%, grades 3-4) at the sixth cycle of chemotherapy ( Figure 1 ). Erythrocyte transfusions were required for 12% of patients with NSCLC during treatment. Among patients with ovarian cancer, the mean hemoglobin levels were determined to be 11.84 6 1.32 g/dL (n 5 52) before chemotherapy, 10.53 6 1.23 g/dL (n 5 51) at the third cycle, and 10.77 6 1.50 g/dL (n 5 46) at the sixth cycle of treatment (Table 2) . Hemoglobin levels at the first and sixth month after chemotherapy were 11.46 6 0.85 g/dL and 12.32 6 0.97 g/dL, respectively. Compared with the baseline values, the decrease in the mean hemoglobin levels was significant at the third cycle (1.31 g/dL, P , 0.0001); however, there was no significant difference in the hemoglobin levels between the third and sixth cycle (P 5 0.55) ( Table 2 ). The frequency of grades 1-2 anemia before treatment was higher in patients with ovarian cancer than in those with NSCLC (28.6% vs. 17.3%) ( Figure 2 ). Anemia was detected in 68.0% of the cases in the third cycle of treatment (62%, grades 1-2 and 6%, grades 3-4) and in 54.1% of the cases in the sixth cycle of treatment (45.9%, grades 1-2 and When patients with lung and ovarian cancer were compared in terms of changes in the hemoglobin values, the decline in the mean hemoglobin levels from the baseline to the third cycle (a 1.44 6 1.22 g/dL decrease in patients with NSCLC and a 1.31 6 1.60 g/dL decrease in patients with ovarian cancer) was not significantly different for either type of cancer (Table 2 ). However, variations in hemoglobin levels were significantly different from the third to the sixth cycle of treatment; there was a decrease in the patients with NSCLC (20.53 6 0.8 g/dL) and an increase in the patients with ovarian cancer (0.13 6 1.3 g/dL, P 5 0.01). Time-and treatment-dependent changes in the hemoglobin values among the patients with NSCLC and ovarian cancer are depicted in Figure 3 .
Effects on leukocytes
In patients with NSCLC, the median leukocyte values were 8.9 3 10 3 /mm 3 at the baseline, 5.1 3 10 3 /mm 3 at the third cycle, and 4.8 3 10 3 /mm 3 at the sixth cycle ( Table 2 ). The median leukocyte values 1 and 6 months after the treatment were 6.5 and 7.2 3 10 3 /mm 3 , respectively. The decline in the median leukocyte values from the baseline to the third cycle was statistically significant (P , 0.001), but there was no evident change in the leukocyte values from the third to the sixth cycle (P 5 0.36). The frequency of baseline grades 1-2 leukopenia was only 3.4% (Figure 4 ). This frequency was 46% at the third cycle (40.0%, grades 1-2 and 6.0%, grades 3-4) and 41.9% at the sixth cycle (32.6%, grades 1-2 and 9.3%, grades 3-4) for patients with NSCLC. No patient was complicated by febrile neutropenia and therefore G-CSF usage was not performed.
Among patients with ovarian cancer, the median leukocyte values were 6.7 3 10 3 /mm 3 at admission, 4.1 3 10 3 /mm 3 at the third cycle, and 3.5 3 10 3 /mm 3 at the sixth cycle ( Table 2) . After the chemotherapy, the leukocyte median values at the first and sixth month of treatment were 7.3 and 6.5 3 10 3 /mm 3 , respectively. The decrease in the median leukocyte values from the baseline to the third cycle was statistically significant (P , 0.0001), but there was no significant change in the median leukocyte values from the third to the sixth cycle of treatment (P 5 0.11). There was no leukopenia among patients with ovarian cancer before treatment; however, the rates of leukopenia were determined to be 41.2% at the third cycle (37.3%, grades 1-2 and 3.9%, grades 3-4) and 48.8% at the sixth cycle of chemotherapy (43.9%, grades 1-2 and 4.9%, grades 3-4) ( Figure 5 ). The G-CSF was needed in none of the patients with ovarian cancer.
Changes in the leukocyte values from the baseline to the third cycle and from the third to the sixth cycle of chemotherapy were found to be similar for each type of cancer (Table 2) . Time-and treatment-dependent changes in the leukocyte values among the patients with NSCLC and ovarian cancer are depicted in Figure 6 .
Effects on platelets
The median thrombocyte values in the patients with NSCLC were 279 3 10 3 /mm 3 before chemotherapy, 204 3 10 3 /mm 3 at the third cycle, and 156 3 10 3 /mm 3 at the sixth cycle of treatment (Table 2) . After the chemotherapy, the thrombocyte values at the first and sixth month of treatment were 222 3 10 3 /mm 3 and 194 3 10 3 /mm 3 , respectively. The decrease in the thrombocyte values from the baseline to the third cycle was statistically significant (P , 0.0001), but there was no significant difference in the thrombocyte values from the third to the sixth cycle (P 5 0.50) of chemotherapy (Table 2) . Thrombocytopenia was not detected at the baseline evaluation among the patients with NSCLC; however, the rates of thrombocytopenia were 12.5% (10%, grades 1-2 and 2.5%, grades 3-4) at the third cycle and 23.3% (20%, grades 1-2 and 3.3%, grades 3-4) at the sixth cycle ( Figure 7 ). Only 1 patient needs thrombocyte transfusion.
Among the patients with ovarian cancer, the median thrombocyte values were 255 3 10 3 /mm 3 before chemotherapy, 234 3 10 3 /mm 3 at the third cycle, and 169 3 10 3 /mm 3 after the completion of treatment ( Table 2) . Thrombocyte values at the first and sixth month after therapy were 235 3 10 3 /mm 3 and 238 3 10 3 /mm 3 , respectively. The decrease in thrombocyte counts continued during the treatment from the baseline to the third cycle and from the third cycle to the sixth cycle of chemotherapy (P 5 0.003 and P , 0.0001, respectively). Thrombocytopenia was not detected before initiation of treatment, but the rates of thrombocytopenia were 10.4% (8.3%, grades 1-2 and 2.1%, grades 3-4) at the third cycle, and 25% (19.4%, grades 1-2 and 5.6%, grades 3-4) at the sixth cycle of therapy ( Figure 8 ). The thrombocyte transfusions were performed to 2 patients. Tas et al Variations in the thrombocyte counts from the baseline to the third cycle and from the third to the sixth cycle were found to be similar for both cancer types ( Table 2) . Time-and treatment-dependent changes in the platelets values among the patients with NSCLC and ovarian cancer are depicted in Figure 9 .
DISCUSSION
The carboplatin-paclitaxel combination is one of the most frequently administered regimens for the first-line treatment of advanced ovarian cancer and NSCLC. This combination is supposed to have similar efficacy with lower nonhematologic side effects when compared with other platinum-based combinations for both lung and ovarian cancers. The most evident side effects of the regimen are peripheral neuropathy and hematologic toxicity (ie, anemia, leukopenia, and thrombocytopenia). In our study, we evaluated and compared the hematologic toxicity of the carboplatin-paclitaxel combination administered as the first-line treatments with the same doses and schedules for patients with ovarian and lung cancer. According to our findings, anemia is more frequently encountered in patients with ovarian cancer who are administered carboplatin-paclitaxel in combination compared with patients with lung cancer. During treatment with this combination, the decreases in hemoglobin levels in patients with NSCLC and in platelet counts in patients with ovarian cancer were statistically significant.
Anemia is a frequently encountered disorder in patients with malignant diseases, especially in those receiving polychemotherapy containing platinum or in those with advanced stages of cancer. The incidence in various malignancies depends on the type of underlying disorder, the stage and duration of the diseases, and the regimen and intensity of the antitumor treatment. In our study, the incidence of anemia was higher in the patients with ovarian cancer compared with the patients with NSCLC. The frequencies of all grades of anemia were 17%, 39.2%, and 44.2% for the patients with NSCLC and 28.6%, 68.0%, and 45.2% for the patients with ovarian cancer at the beginning of the treatment and at the third and sixth cycle of treatment, respectively. Most of the patients with NSCLC were men and smokers (in our study, 86.5% and 80.7%, respectively). As expectedly, the hemoglobin values in men and smokers were higher compared with women and nonsmoker counterparts. In addition, patients with ovarian cancer are prone to dilutional anemia due to the presence of high-volume overload, which is triggered by activation of the renin-angiotensin-aldosterone system in response to ascites, especially before treatment. In our study, the incidence and degree of anemia was higher at the third cycle of chemotherapy compared with pretreatment due to treatment toxicity and at the sixth cycle hemoglobin values that were decreased as a consequence of disease burden, ascites, and, indirectly, dilutional anemia. The incidence of anemia among the patients with NSCLC before treatment was 17%, possibly due to both a paraneoplastic effect and a bone marrow infiltration. In addition, hemoglobin levels decreased progressively and significantly throughout the treatment in these patients; compared with the baseline, there was a 1.44 mg/dL decrease in the third cycle and a 0.53 mg/dL decrease between the third and sixth cycle. According to the literature, the treatment-related anemia is higher in patients with ovarian cancer and NSCLC compared with other cancer types. A prospective review that included 616 patients with cancer who received chemotherapy at 12 Canadian medical centers revealed low proportions of treatment-associated anemia in patients with colorectal (13.8%) and breast cancers (15.6%), whereas higher rates of anemia were observed in patients with ovarian (51%) and lung cancers (52%). 12 Furthermore, the retrospective analysis of 552 patients at our institute performed by Tas et al 13 revealed a higher rate of treatment-related anemia among patients with ovarian cancer and NSCLC compared with other cancer types. In the same study, chemotherapy resulted in a significant decrease in hemoglobin levels when compared with pretreatment values in patients with lung cancer (P , 0.001). In addition, there was a prominent decline in the hemoglobin levels with platin-based combinations in contrast to combinations including nonplatin agents.
In this study, the incidences of all grades of leukopenia were determined to be 3.4%, 46.0%, and 41.9% among the patients with NSCLC and 0%, 41.2%, and 48.8% among the patients with ovarian cancer at the baseline and at the third and sixth cycle of treatment, respectively. In a phase III study performed in patients with advanced treatment-naive NSCLC, the rate of all grades of leukopenia was reported to be 74% and the rate of grades 3-4 leukopenia was 23% after administration of carboplatin-paclitaxel chemotherapy. 14 In another phase III study involving patients with ovarian cancer, the incidence of all grades of leukopenia was determined to be 67% and the incidence of grades 3-4 leukopenia was 19%. 15 In our study, thrombocytopenia is the least observed side effect in both cancer types, which is in accordance with the results of previous randomized studies. In a phase III study performed in patients with advanced ovarian cancer treated with paclitaxel-carboplatin, the rate of all grades of thrombocytopenia was 19%. 15 In another phase III study of patients with NSCLC, the rate was 27%. 14 In our study, the incidences of thrombocytopenia at the baseline and at the third and sixth cycle of therapy were 0%, 12.5%, and 23.3% among the patients with NSCLC and 0%, 10.4%, and 25% for the patients with ovarian cancer, respectively. In patients with both NSCLC and ovarian cancer, there were significant declines in thrombocyte counts at the third cycle of chemotherapy compared with pretreatment values. There was no significant reduction of thrombocytes from the third to the sixth cycle of treatment in patients with NSCLC; however, patients with ovarian cancer exhibited significantly more pronounced thrombocytopenia that persisted through the course of treatment.
In conclusion, the incidence of anemia was higher in the patients with ovarian cancer who were given the carboplatin-paclitaxel combination compared with the patients with lung cancer. In addition, the decreases in hemoglobin values in the patients with NSCLC and thrombocyte values in the patients with ovarian cancer were statistically significant during the treatment. Using the same dose and schedule can lead to different myelotoxicities in different cancer types. These results should be taken into consideration in terms of supportive care and management of toxicity.
